Dublin, July 23, 2026 (GLOBE NEWSWIRE) — The “Fill Finish Manufacturing Market by Consumables, Instruments, Type, Services, Competition – Global Forecast to 2031” has been added to ResearchAndMarkets.com’s offering.
The global fill finish manufacturing market is projected to grow from USD 19.75 billion in 2026 to USD 30.37 billion by 2031, registering a compound annual growth rate of 9.0% during the forecast period. Expansion of biologics, biosimilars, vaccines, injectable drugs, and advanced therapy pipelines is increasing demand for sterile fill-finish manufacturing capacity worldwide.
Market growth is also supported by increased outsourcing to contract development and manufacturing organizations (CDMOs), alongside technological advances in aseptic filling, isolator systems, robotics, automation, gloveless isolators, and ready-to-use components. High capital expenditure, lengthy capacity-addition timelines, stringent regulatory requirements, operational complexity, and shortages of skilled sterile manufacturing personnel may partially constrain expansion.
Consumables Led the Fill Finish Manufacturing Market in 2025
By product, the market is segmented into consumables and instruments. Consumables accounted for the largest market share in 2025 due to their recurring use in filling, containment, inspection, and packaging operations. Vials, prefilled syringes, cartridges, stoppers, seals, and other container-and-closure components are required for every production batch, generating sustained demand.
Increasing production of biologics, biosimilars, vaccines, and advanced therapies is strengthening the segment. Pharmaceutical companies and CDMOs are also adopting ready-to-use components and single-use technologies to improve operational flexibility, reduce contamination risk, and support scalable sterile manufacturing.
Contract Manufacturing Organizations Held the Largest End-User Share
Based on end user, the fill finish manufacturing market includes contract manufacturing organizations (CMOs), pharmaceutical and biopharmaceutical companies, and other end users. CMOs held the largest share in 2025 as pharmaceutical and biotechnology companies increasingly outsourced sterile manufacturing to reduce costs, gain specialized expertise, access flexible capacity, and accelerate commercialization.
CMOs provide advanced aseptic processing capabilities, scalable production services, and established regulatory compliance systems for biologics, biosimilars, vaccines, and injectable drugs. Continued demand for high-quality sterile manufacturing services is expected to reinforce their market position through 2031.
Asia Pacific to Register the Highest CAGR Through 2031
The report analyzes North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific is forecast to record the highest CAGR from 2026 to 2031, supported by expanding biopharmaceutical manufacturing, investment in sterile injectable production, and growing regional demand for biologics, biosimilars, and vaccines.
Further growth is anticipated from the expansion of CDMO services, adoption of advanced aseptic filling technologies, and manufacturing infrastructure investments across China, India, South Korea, and Japan. Established manufacturing hubs and continued capacity expansions are strengthening Asia Pacific’s role in the global fill finish manufacturing market.
Market Drivers, Opportunities, Restraints, and Challenges
Major growth drivers include demand for GLP-1 and incretin injectables for obesity, which is outpacing available capacity, and the expansion of biosimilar and antibody-drug conjugate pipelines. EU GMP Annex 1 compliance and global sterile manufacturing regulatory harmonization are encouraging capital investment in isolators, restricted access barrier systems, robotics, automation, and gloveless isolator technologies.
Emerging opportunities include cell and gene therapy and mRNA small-batch manufacturing, automated visual inspection, container closure integrity testing, predictive analytics integration, and radiopharmaceutical and theranostic drug-product fill-finish services. Radiopharmaceuticals and theranostics are identified as a high-growth niche segment.
Key restraints include price pressure in sterile generics and hospital injectables, workforce limitations, high capital costs, and long lead times for capacity additions. Oral peptides and GLP-1 drug-delivery alternatives may also restrict fill-finish volume growth. Sustainability requirements and the high energy intensity of sterile manufacturing remain significant industry challenges.
Competitive Landscape
The report evaluates established companies and emerging participants, including business overviews, product portfolios, market shares, growth strategies, product and service approvals, launches, collaborations, partnerships, expansions, agreements, investments, and recent developments. Companies profiled include:
- West Pharmaceutical Services Inc.
- BD & Co.
- Syntegon Technology GmbH
- I.M.A. S.P.A.
- Gerresheimer AG
- AptarGroup Inc.
- Dätwyler Holding Inc.
- Danaher
- Stevanato Group S.p.A.
- OPTIMA
- Bausch+Ströbel
- Groninger & Co. GmbH
- SCHOTT
- Nipro Corporation
- Bausch Advanced Technology Group
- Maquinaria Industrial Dara SI
Key Attributes
| Report Attribute | Details |
| No. of Pages | 466 |
| Forecast Period | 2026-2031 |
| Estimated Market Value (USD) in 2026 | $19.75 Billion |
| Forecasted Market Value (USD) by 2031 | $30.37 Billion |
| Compound Annual Growth Rate | 9% |
| Regions Covered | Global |
Market Dynamics
Drivers
- Rapid Adoption of Glp-1/Incretin Injectables For Obesity Driving Demand
- Biosimilars & Adc Pipeline Expansion Driving Sterile Injectable Contract Manufacturing Growth
- EU Gmp Annex 1 Compliance & Global Sterile Manufacturing Harmonization Driving Capital Investment For Isolators and Rabs
- Robotics, Automation, and Gloveless Isolator Technologies Gaining Traction
Challenges
- Restraints
- Price Pressure in Sterile Generics and Hospital Injectables
- Workforce Constraints in Sterile Manufacturing Operations
- High Capex and Long Lead Times Constraining Fill-Finish Capacity Addition
- Oral Peptides and Oral Glp-1 Drug Delivery Restraining Fill-Finish Volume Growth
- Sustainability Pressure and High Energy Intensity of Sterile Manufacturing
Opportunities
- Growing Demand For Cell & Gene Therapy/Mrna Small-Batch Manufacturing
- Rising Need For Automated Visual Inspection and Container Closure Integrity Testing
- Integration of Predictive Analytics
- Radiopharmaceutical and Theranostic Drug Product Fill-Finish Emerging As High-Growth Niche
For more information about this report visit https://www.researchandmarkets.com/r/ykqhoj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Fill Finish Manufacturing Market
